EYLEA (aflibercept), anti-VEGF

Moderate clinical added value, as is the case with LUCENTIS, in visual impairment due to myopic choroidal neovascularisation

• EYLEA has Marketing Authorisation in adults, in the treatment of visual impairment due to myopic choroidal neovascularisation (CNV).
• A study has demonstrated a substantial improvement in visual acuity by comparison with sham intravitreal injections (+14.1 letters on the ETDRS scale).
• Despite the absence of comparative data versus ranibizumab, EYLEA may be considered a 1^st line treatment just as LUCENTIS in this indication.